NLS Pharmaceutics
| General Information | |
| Business: | We are an innovative biopharmaceutical company engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders, including narcolepsy and ADHD (Attention Deficit Hyperactivity Disorder). CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders. (Note: This is a unit offering.) |
| Industry: | PHARMACEUTICAL PREPARATIONS |
| Employees: | 4 |
| Founded: | 2015 |
| Contact Information | |
| Address | Alter Postplatz 2, CH-6370 Stans, Switzerland |
| Phone Number | +41.79.779.60.00 |
| Web Address | |
| View Prospectus: | NLS Pharmaceutics |
| Financial Information | |
| Market Cap | $58.3mil |
| Revenues | $0 mil (last 12 months) |
| Net Income | $-6.5 mil (last 12 months) |
| IPO Profile | |
| Symbol | NLSP |
| Exchange | NASDAQ |
| Shares (millions): | 4.8 |
| Price range | $4.15 - $4.15 |
| Est. $ Volume | $20.0 mil |
| Manager / Joint Managers | Maxim Group LLC |
| CO-Managers | Brookline Capital (A division of Arcadia Securities) |
| Expected To Trade: | 1/29/2021 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |